Summary
Antibody-detection related to disease or to drug monitoring demands novel IVD tests that provide robust, rapid and early- stage diagnostics for improved and early on-set treatments. However, companies developing novel IVD immunoassays face an important barrier related to reimbursement policy issues when the IVD tests are introduced into national health systems. This barrier discourages many companies from pursuing the development of novel diagnostic tests because the investment necessary to introduce novel IVD tests in the market is hardly matched by the return of the investment. NIMM aims at providing a platform for the development of accurate, sensitive and inexpensive immunoassays for antibody-related conditions using a novel fluorescent nanosensor-based technology. The outcome of the project will pave the way to a commercial product to be sold in the Immunochemistry/Immunoassay segment of the IVD market, currently valued at 15 USD billion. Potential stakeholders in the outcome of NIMM include Public Health authorities and pharmaceutical companies.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/841063 |
| Start date: | 01-07-2019 |
| End date: | 30-06-2021 |
| Total budget - Public funding: | 149 952,00 Euro - 149 952,00 Euro |
Cordis data
Original description
Antibody-detection related to disease or to drug monitoring demands novel IVD tests that provide robust, rapid and early- stage diagnostics for improved and early on-set treatments. However, companies developing novel IVD immunoassays face an important barrier related to reimbursement policy issues when the IVD tests are introduced into national health systems. This barrier discourages many companies from pursuing the development of novel diagnostic tests because the investment necessary to introduce novel IVD tests in the market is hardly matched by the return of the investment. NIMM aims at providing a platform for the development of accurate, sensitive and inexpensive immunoassays for antibody-related conditions using a novel fluorescent nanosensor-based technology. The outcome of the project will pave the way to a commercial product to be sold in the Immunochemistry/Immunoassay segment of the IVD market, currently valued at 15 USD billion. Potential stakeholders in the outcome of NIMM include Public Health authorities and pharmaceutical companies.Status
CLOSEDCall topic
ERC-2018-PoCUpdate Date
27-04-2024
Geographical location(s)
